Tucatinib fills a specific and clinically important gap in HER2-positive breast cancer treatment — its ability to cross the blood-brain barrier means it's one of the few oral HER2-targeted therapies that actually provides benefit for patients whose cancer has spread to the brain, a genuinely difficult-to-treat complication that many other HER2 therapies simply don't address effectively.
- Approved indication: HER2-positive advanced or metastatic breast cancer, including cases with brain metastases, typically given in combination with Trastuzumab and capecitabine after prior HER2-directed therapies have been tried
- Mechanism: A tyrosine kinase inhibitor that specifically and selectively targets the HER2 receptor, blocking downstream signaling pathways that drive tumor growth, while penetrating the blood-brain barrier
- Standard dosing: Typically 300mg twice daily (two 150mg tablets morning and evening), taken with or without food
- Clinical differentiator: Demonstrated efficacy specifically in patients with brain metastases — a distinct clinical advantage worth highlighting to oncology centers treating advanced HER2-positive disease
- Hepatotoxicity: Requires regular liver function testing throughout treatment — elevated liver enzymes are a recognized risk
- Diarrhea: A very common side effect requiring proactive management protocol, including guidance on oral rehydration
- Drug interactions: Significant interactions with azole antifungals, macrolide antibiotics, rifampin/rifabutin, certain anticonvulsants, and St. John's Wort — a detailed medication history is essential before starting
- Pregnancy/breastfeeding: Not recommended; effective contraception required during treatment and for at least 1 week after the last dose
- Missed dose guidance: If more than 8 hours have passed since a missed dose, it should be skipped rather than doubled up at the next scheduled time
- Certification: WHO-GMP tablet manufacturing
- Batch-specific testing: Dissolution and bioequivalence testing per batch
Documentation & Availability:
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: In stock, both 50mg and 150mg strengths | Quote turnaround: 24 hours
- Logistics: Standard export logistics, no cold chain required
- Coverage: Global export markets
- Tracking: Full shipment tracking included
- Institutional buyers: Hospital and pharmacy distributor support, particularly relevant for oncology centers treating HER2-positive patients with brain metastases
- Unregistered markets: Named-patient supply pathway available
What is Tucatinib used for?
Treats HER2-positive metastatic breast cancer, including cases that have spread to the brain, combined with Trastuzumab and capecitabine.
Get Tucatinib price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Does it help with brain metastases?
Yes, it's one of the few oral HER2-targeted therapies shown to cross the blood-brain barrier and provide clinical benefit for brain metastases.
What is the usual dose?
Typically 300mg twice daily, taken as two 150mg tablets in the morning and two in the evening.
Who supplies Tucatinib from India?
WHO-GMP certified tablet manufacturing with full export documentation.
